It should be noted that other new treatments, including BCL-2 homology domain 3 (BH3) mimetics, or Phosphoinositide 3-kinase (PI3K) and AKT Serine/Threonine Kinase (AKT) inhibitors, have also been successfully introduced – and these are all examples of targeted therapies that are rationally designed and aimed at specific molecular nodes in the tumor. This evidence concerns the gene AKT1 and neoplasm.